Sunitinib in advanced pancreatic neuroendocrine tumors: Latest evidence and clinical potential

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 1, 2012, Pages 9-18

  Delbaldo, Catherine ^a   Faivre, Sandrine ^a   Dreyer, Chantal ^a   Raymond, Eric ^a  

^a INSERM   (France)

Author keywords

analogs; angiogenesis; endocrine tumors; mTOR inhibitor; PDGFR; somatostatin combinations; VEGFR

Indexed keywords

ANTINEOPLASTIC AGENT; PLACEBO; SU 012662; SUNITINIB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN EDEMA; SKIN TOXICITY;

EID: 84856888780     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834011428147     Document Type: Review

References (55)

1. Abrams T.J. Lee L.B. Murray L.J. Pryer N.K. Cherrington J.M. (2003 a) SU 11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471–478.
2. Abrams T.J. Murray L.J. Pesenti E. Holway V.W. Colombo T. Lee L.B. et al. (2003 b) Preclinical evaluation of the tyrosine kinase inhibitor SU 11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2: 1011–1021.
3. Ahmad T. Eisen T. (2004) Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res 10: 6388S–6392S.
4. Arnold R. (2005) Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options. Best Pract Res Clin Gastroenterol 19: 491–505.
5. Ballian N. Loeffler A.G. Rajamanickam V. Norstedt P.A. Weber S.M. Cho C.S. (2009) A simplified prognostic system for resected pancreatic neuroendocrine neoplasms. HPB (Oxford) 11: 422–428.
6. Baratte S. Sarati S. Frigerio E. James C.A. Ye C. Zhang Q. (2004) Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction. J Chromatogr 1024: 87–94.
7. Botchkareva N.V. Khlgatian M. Longley B.J. Botchkarev V.A. Gilchrest B.A. (2001) SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 15: 645–658.
8. Britten C.D. Kabbinavar F. Hecht J.R. Bello C.L. Li J. Baum C. et al. (2008) A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 61: 515–524.
9. Casanovas O. Hicklin D.J. Bergers G. Hanahan D. (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299–309.
10. Couvelard A. Deschamps L. Ravaud P. Baron G. Sauvanet A. Hentic O. et al. (2009) Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 22: 273–281.
11. Couvelard A. O'Toole D. Turley H. Leek R. Sauvanet A. Degott C. et al. (2005) Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer 17 (92): 94–101.
12. Demetri G.D. van Oosterom A.T. Garrett C.R. Blackstein M.E. Shah M.H. Verweij J. et al. (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 368: 1329–1338.
13. Eriksson B. Annibale B. Bajetta E. Mitry E. Pavel M. Platania M. et al. (2009) ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90: 214–219.
14. Etienne G. Cony-Makhoul P. Mahon F.X. (2002) Imatinib mesylate and gray hair. N Engl J Med 347: 446.
15. Faivre S. Delbaldo C. Vera K. Robert C. Lozahic S. Lassau N. et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24: 25–35.
16. Faivre S. Demetri G. Sargent W. Raymond E. (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6: 734–745.
17. Hemesath T.J. Price E.R. Takemoto C. Badalian T. Fisher D.E. (1998) MAP kinase links the transcription factor Microphthalmia to c-Kit signaling in melanocytes. Nature 391: 298–301.
18. Heng P.N. Saltz L.B. (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86: 944–948.
19. Inoue M. Hager J.H. Ferrara N. Gerber H.P. Hanahan D. (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1: 193–202.
20. Kitamura R. Tsukamoto K. Harada K. Shimizu A. Shimada S. Kobayashi T. et al. (2004) Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: Role of SCF / KIT protein interactions and the downstream effector, MITF-M. J Pathol 202: 463–475.
21. Kloppel G. Anlauf M. (2005) Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol 19: 507–517.
22. Knigge U. Hansen C.P. Stadil F. (2008) Interventional treatment of neuroendocrine liver metastases. Surgeon 6: 232–239.
23. Kouvaraki M.A. Ajani J.A. Hoff P. Wolff R. Evans D.B. Lozano R. et al. (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22: 4762–4771.
24. Kuenen B.C. Levi M. Meijers J.C. van Hinsbergh V.W. Berkhof J. Kakkar A.K. et al. (2003) Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 21: 2192–2198.
25. Kulke M.H. Lenz H.J. Meropol N.J. Posey J. Ryan D.P. Picus J. et al. (2008) Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26: 3403–3410.
26. Marx G.M. Steer C.B. Harper P. Pavlakis N. Rixe O. Khayat D. (2002) Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: Time to take stock! J Clin Oncol 20: 1446–1448.
27. McCollum A.D. Kulke M.H. Ryan D.P. Clark J.W. Shulman L.N. Mayer R.J. et al. (2004) Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol 27: 485–488.
28. Mendel D.B. Laird A.D. Xin X. Louie S.G. Christensen J.G. Li G. et al. (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic / pharmacodynamic relationship. Clin Cancer Res 9: 327–337.
29. Moertel C.G. Hanley J.A. Johnson L.A. (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303: 1189–1194.
30. Moertel C.G. Kvols L.K. O'Connell M.J. Rubin J. (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68: 227–232.
31. Moertel C.G. Lefkopoulo M. Lipsitz S. Hahn R.G. Klaassen D. (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326: 519–523.
32. Morimoto A.M. Tan N. West K. McArthur G. Toner G.C. Manning W.C. et al. (2004) Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. Oncogene 23: 1618–1626.
33. Moss K.G. Toner G.C. Cherrington J.M. Mendel D.B. Laird A.D. (2003) Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans. J Pharmacol Exp Ther 307: 476–480.
34. Motzer R.J. Hutson T.E. Tomczak P. Michaelson M.D. Bukowski R.M. Rixe et al. (2007) Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Eng J Med 356: 115–124.
35. Murray L.J. Abrams T.J. Long K.R. Ngai T.J. Olson L.M. Hong W. et al. (2003) SU 11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20: 757–766.
36. O'Farrell A.M. Foran J.M. Fiedler W. Serve H. Paquette R.L. Cooper M.A. et al. (2003) An innovative phase I clinical study demonstrates inhibition of FLT 3 phosphorylation by SU 11248 in acute myeloid leukemia patients. Clin Cancer Res 9: 5465–5476.
37. Osusky K.L. Hallahan D.E. Fu A. Ye F. Shyr Y. Geng L. (2004) The receptor tyrosine kinase inhibitor SU 11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effects on existing tumor vessels. Angiogenesis 7: 225–233.
38. Pàez-Ribes M. Allen E. Hudock J. Takeda T. Okuyama H. Viñals F. et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220–231.
39. Pietras K. Hanahan D. (2005) A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23: 939–952.
40. Raymond E. Dahan L. Raoul J.L. Bang Y.J. Borbath I. Lombard-Bohas C. et al. (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364: 501–513.
41. Raymond E. Faivre S. Hammel P. Ruszniewski P. (2009) Sunitinib paves the way for targeted therapies in neuroendocrine tumors. Target Oncol 4: 253–254.
42. Rinke A. Muller H.H. Schade-Brittinger C. Klose K.J. Barth P. Wied M. et al. (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol 27: 4656–4663.
43. Robert C. Faivre S. Raymond E. Armand J.P. Escudier B. (2005) Sublingual splinter hemorrhages: A clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 143: 313–314.
44. Robert C. Spatz A. Faivre S. Armand J.P. Raymond E. (2003) Tyrosine kinase inhibition and grey hair. Lancet 361: 1056.
45. Rouffiac V. Bouquet C. Lassau N. Opolon P. Koscielny S. Peronneau P. et al. (2004) Validation of a new method for quantifying in vivo murine tumor necrosis by sonography. Invest Radiol 39: 350–356.
46. Theou-Anton N. Faivre S. Dreyer C. Raymond E. (2009) Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer. Drug Safety 32: 717–734.
47. Tsao A.S. Kantarjian H. Cortes J. O'Brien S. Talpaz M. (2003) Imatinib mesylate causes hypopigmentation in the skin. Cancer 98: 2483–2487.
48. Vilar E. Salazar R. Perez-Garcıa J. Cortes J. Oberg K. Tabernero J. (2007) Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 14: 221–232.
49. Willett C.G. Boucher Y. di Tomaso E. Duda D.G. Munn L.L. Tong R.T. et al. (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10: 145–147.
50. Yang J.C. Haworth L. Sherry R.M. Hwu P. Schwartzentruber D.J. Topalian S.L. et al. (2003). A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427–434.
51. Yao J.C. Shah M.H. Ito T. Bohas C.L. Wolin E.M. van Cutsem E. et al. (2011) RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514–523.
52. Yao K.A. Talamonti M.S. Nemcek A. Angelos P. Chrisman H. Skarda J. et al. (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130: 677–682.
53. Yao V.J. Sennino B. Davis R.B. (2006) Combined anti-VEGFR and anti-PDGFR actions of sunitinib on blood vessels in preclinical tumor models. Eur J Cancer 4 (27): 8.
54. Yee K.W. Schittenhelm M. O'Farrell A.M. Town A.R. McGreevey L. Bainbridge T. et al. (2004) Synergistic effect of SU 11248 with cytarabine or daunorubicin on FLT3-ITD positive leukemic cells. Blood 104: 4202–4209.
55. Zhang J. Jia Z. Li Q. Wang L. Rashid A. Zhu Z. et al. (2007) Elevated expression of vascular endothelial growth factor VEGF correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 109: 1478–1486.